Dec 22 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Headlines

Novavax jab triggers immune response to Omicron https://on.ft.com/3Jg93HR

White House warns Pfizer Covid-19 pill will not be widely available for months https://on.ft.com/3Enw20b

UK and EU strike deal on access to fish stocks in 2022 https://on.ft.com/3EgzY2N

Only vulnerable eligible for Covid jab in UK rollout for 5- to 11-year-olds https://on.ft.com/3suOt0y

Overvie

Novavax Covid-19 vaccine appears to generate an effective immune response against the Omicron variant, according to preliminary data released by the drugmaker on Wednesday.

White House has warned it will take more than six months to fulfil its initial order for Pfizer's antiviral Covid-19 pill, as officials damped speculation the drug could immediately turn the tables on the pandemic.

UK and EU have struck a deal on sharing fish stocks in 2022, while a separate dispute with France over access for its boats in British waters continues.

Only five- to 11-year-olds who are vulnerable will be eligible for the BioNTech/Pfizer, Covid jab in the UK, following recommendation from the government's vaccine advisers, despite the medicines regulator approving the shot for all children in the age group.

(Compiled by Bengaluru newsroom)